Bulletin
Investor Alert

Intra-Cellular Therapies Inc.

NAS: ITCI

GO
/marketstate/country/us

After Hours

/zigman2/quotes/209441868/composite

$

60.00

Change

+2.10 +3.63%

Volume

Volume 30,591

Jun 27, 2022, 6:12 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/209441868/composite

Today's close

$ 55.62

$ 57.90

Change

+2.28 +4.10%

Day low

Day high

$55.97

$59.04

Open
Open: 56.20

52 week low

52 week high

$28.40

$66.00

Open

Market cap

$5.25B

Average volume

872,018

P/E ratio

N/A

Rev. per Employee

$163,678

EPS

-3.62

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/itci

MarketWatch News on ITCI

  1. Intra-Cellular Therapies started at buy with $75 stock price target at UBS

    10:52 a.m. June 14, 2022

    - Tomi Kilgore

  2. The FDA Is About to Make Some Major Drug Decisions

    2:51 p.m. Oct. 16, 2021

    - Barron's Online

  3. Intra-Cellular Therapies downgraded to neutral from overweight at J.P. Morgan

    8:54 a.m. Jan. 31, 2020

    - Tomi Kilgore

  4. Intra-Cellular Therapies stock price target raised to $65 vs. $29 at Canaccord

    11:48 a.m. Dec. 24, 2019

    - Ciara Linnane

  5. Intra-Cellular Therapies reiterated as buy at Canaccord

    11:48 a.m. Dec. 24, 2019

    - Ciara Linnane

  6. Intra-Cellular Therapies gets FDA approval for schizophrenia treatment

    8:14 a.m. Dec. 23, 2019

    - Ciara Linnane

  7. Intra-Cellular Therapies stock soars 42% premarket

    8:14 a.m. Dec. 23, 2019

    - Ciara Linnane

  8. Intra-Cellular Therapies shares slide 7% after resuming trade following halt.

    7:36 a.m. July 8, 2019

    - Ciara Linnane

  9. Intra-Cellular announces positive results in late-stage trial of treatment for bipolar depression

    7:05 a.m. July 8, 2019

    - Ciara Linnane

  10. Intra-Cellular Therapies and Sol-Gel Technologies halted for news pending

    6:58 a.m. July 8, 2019

    - Ciara Linnane

  11. Intra-Cellular Therapies started at overweight with $25 stock price target at J.P. Morgan

    8:59 a.m. Feb. 26, 2018

    - Tomi Kilgore

  12. Intra-Cellular Therapies upgraded to buy from hold at SunTrust RH

    9:30 a.m. Nov. 9, 2017

    - Tomi Kilgore

  13. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/itci

Other News on ITCI

  1. Intra-Cellular Therapies: A Dramatic Story

    3:24 a.m. June 18, 2022

    - Seeking Alpha

  2. Wasatch Core Growth Fund Q1 2022 Commentary

    10:56 a.m. May 25, 2022

    - Seeking Alpha

  3. Wasatch Small Cap Value Fund Q1 2022 Commentary

    10:26 a.m. May 25, 2022

    - Seeking Alpha

  4. Wasatch Ultra Growth Fund Q1 2022 Commentary

    9:19 a.m. May 25, 2022

    - Seeking Alpha

  5. Why Intra-Cellular Therapies Stock Rose 21.4% This Week

    5:34 p.m. May 12, 2022

    - Motley Fool

  6. Why Intra-Cellular Therapies Trounced the S&P 500 Today

    6:24 p.m. May 10, 2022

    - Motley Fool

  7. 10-Q: INTRA-CELLULAR THERAPIES, INC.

    7:49 a.m. May 10, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  8. Intra-Cellular Therapies Q1 2022 Earnings Preview

    12:31 p.m. May 9, 2022

    - Seeking Alpha

  9. Notable earnings before Tuesday's open

    11:06 a.m. May 9, 2022

    - Seeking Alpha

  10. Acadia: Catalysts Stacking

    6:16 p.m. April 28, 2022

    - Seeking Alpha

  11. Vanda: A Dual Growth And Value Player

    2:43 p.m. April 11, 2022

    - Seeking Alpha

  12. Intra-Cellular: Not Participating In A Bear Market

    8:27 a.m. March 31, 2022

    - Seeking Alpha

  13. Loading more headlines...
/news/pressrelease/company/us/itci

Press Releases on ITCI

  1. What Stocks To Buy This Week? 4 Biotech Stocks To Know

    11:20 a.m. May 15, 2022

    - StockMarket.com

  2. Intra-Cellular Therapies Inc. (ITCI): The Winning Streak Continues

    11:44 a.m. Feb. 16, 2022

    - Investor Brand Network

  3. Intra-Cellular Therapies Prices Public Offering of Common Stock

    11:05 p.m. Jan. 4, 2022

    - GlobeNewswire

  4. Loading more headlines...

Rates »

Link to MarketWatch's Slice.